Innate Pharma has finally called time on an NK cell engager in phase 1/2 development as part of an ongoing fine-tuning of the ...
ImmunityBio Inc. (NASDAQ:IBRX) is one of the 10 Must-Watch Stocks Right Now. ImmunityBio surged by 7.29 percent on Friday to finish at $8.39 apiece, as investors took heart from the company’s optimism ...
SNAP Biosciences, a subsidiary of Coeptis Therapeutics Holdings, has entered into a licensing agreement with Monarch Therapeutics to develop and commercialize its Snap-Car NK cell therapy platform for ...
Dr. Song’s presentation will detail how enhanced natural killer cells can maximize the body’s ability to destroy diseased and abnormal cells and provide a review of NK cell therapy as an alternative ...
NÖK Therapeutics, Inc. (“NÖK” or the “Company”), a clinical-stage biotechnology company advancing autologous Natural Killer (“NK”) cell immunotherapies, today announced that its Chief Executive ...
ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...
CD Formulation Demonstrates Expertise in CAR-T and CAR-NK Cell Development for Drug Delivery Systems
CD Formulation further strengthened its role as a drug delivery expert by demonstrating its expertise in the development of cutting-edge CAR-T and CAR-NK cells. NY ...
Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 for a total of 12 billion cells per cycleInitial clinical data from Ntrust-1 and Ntrust-2 targeted for presentation ...
Pharmaceutical companies are shifting from the development of autologous cell therapies to allogeneic cell therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results